1Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA.1999 ;282(8): 786-790.
2Johnston K. What are surrogate outcome measures and why do they fail in clinical research? Neuroepidemiology 1999; 18(4): 167-173.
4Chuang-Stein C, DeMasi R. Surrogate endpoints in AIDS drug development: current status. Drug Information J 1998;32: 439-448, 457-459.
5Gould AL. Discussion of "Surrogate endpoints in AIDS drug evelopment: current status" by C. Chuang-Stein and Ralph DeMasi. Drug Information J 1998 ;32: 453-456.
6Hill AM, DeMasi R, Dawson D. Meta-analysis of antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death. Antivir Ther 1998 ;3(3) :139-145.
7Ellenberg SS. Commentary on "Surrogate endpoints in AIDS drug development: current status"by C. chuang-stein and R.DeMasi. Drug Information J 1998;32:453-456.
8Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253-259.
9Echt DS, Leibson PR, Mitchel LB, et al. Cardiac arrhythmia suppression trial. N Engl J Med. 1989 ;321:406.
10Fleming TR, De Mets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med, 1996; 125 (7):605-613.
